« Return to News | CROs/Service Providers

PharMerica adopts poison pill to prevent takeover

Friday, August 26, 2011 01:25 PM

U.S. pharmacy services provider PharMerica adopted a poison pill to prevent hostile takeovers, two days after Omnicare went public with its bid to acquire the company for $441 million, according to Reuters.

The stockholder rights plan -- commonly referred to as a poison pill -- gives the company the right to issue new shares if a shareholder acquires a 15% stake or more, thus diluting the holdings of the shareholder.

PharMerica rejected Omnicare's bid saying it undervalued the company and could run into regulatory hurdles.

Deutsche Bank Securities is acting as financial adviser for PharMerica.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.